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ABSTRACT
Introduction: The objective of this study was to
compare the efficacy and safety of olopatadine
versus epinastine in healthy Japanese adults
with a history of allergic conjunctivitis to
Japanese cedar pollen.
Methods: This Phase IV double-blind
randomized controlled clinical trial comprised
three clinical visits over 30 days. Screening tests
were performed to identify subjects with a
history of allergic conjunctivitis to Japanese
cedar pollen in terms of skin sensitivity and
positive bilateral reactions to a conjunctival
allergen challenge (CAC) with Japanese cedar
pollen at Visit 1, and confirmation by a positive
bilateral CAC reaction at Visit 2. At Visit 3, the
subjects were randomized to receive one drop of
olopatadine HCl ophthalmic solution 0.1%
(olopatadine) in the left or right eye (1:1
ratio). All subjects received one drop of
epinastine HCl ophthalmic solution 0.05%
(epinastine) in the contralateral eye as an
active control. Five min later, the subjects
underwent bilateral CAC tests with one drop
of the allergen solution at the concentration
that elicited positive reactions at Visits 1 and 2.
Efficacy outcomes included the severity of
ocular itching at 5, 7, and 15 min and the
severity of conjunctival hyperemia at 7, 15, and
20 min after the CAC test, as graded by the
investigator by biomicroscopy.
Results: Fifty people participated in this study
(25 per group). Olopatadine significantly
reduced ocular itching at 7 and 15 min (both
p\0.05) and conjunctival hyperemia at 7 and
20 min (p = 0.0010 and p\0.05, respectively)
after allergen exposure compared with
epinastine. There were no adverse events for
either treatment.
Conclusion: The results of this single-dose
study suggest that olopatadine is superior to
Trial Registration: University Hospital Medical
Information Network clinical trial registry identifier:
UMIN000013943.
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epinastine in terms of suppressing ocular
itching and hyperemia induced by Japanese
cedar pollen during CAC tests. Further studies
are needed to confirm these findings in real-life
settings.
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INTRODUCTION
Seasonal allergic conjunctivitis (SAC) is the
most common form of ocular allergy and is
thought to affect 15–20% of people worldwide
[1, 2]. SAC is associated with several transient
symptoms, especially ocular itching,
hyperemia, and chemosis. These symptoms
typically occur during seasonal elevations in
ambient pollen concentrations [1, 2]. The
pathophysiology of SAC is primarily driven by
the release of histamine from mast cells and the
binding of histamine to topical H1 receptors [3].
Current treatments include multi-target drugs
with anti-histamine and anti-inflammatory
properties that typically suppress the
symptoms of SAC and stabilize mast cell
activity [4].
Japanese cedar pollinosis is a common
disease with an age-adjusted estimated
prevalence of 19.4% in Japan [5], and is
considered to be a national affliction [6].
Japanese cedar pollen is released in early
February and March, and is the most
abundant type of pollen in early spring in
Japan [5, 6]. Japanese cedar pollinosis is
characterized by nasal symptoms such as
sneezing and rhinorrhea, as well as severe
ocular itching [6]. Several topical ophthalmic
solutions with anti-histamine and anti-
inflammatory activities that stabilize mast cell
activity are now available in Japan, including
ketotifen fumarate 0.05% (ketotifen),
levocabastine hydrochloride 0.05%
(levocabastine), epinastine hydrochloride
0.05% (epinastine), and olopatadine
hydrochloride 0.1% (olopatadine) [7]. Oral
preparations of epinastine and olopatadine
have also been developed and provide
systemic relief from allergic disease, although
the ophthalmic effects of these preparations
have not been extensively evaluated.
Prior studies have demonstrated that
olopatadine is more effective than epinastine
[8], levocabastine [9], and ketotifen [10] in
terms of alleviating the symptoms after a
conjunctival allergen challenge (CAC) test in
humans. To our knowledge, however, no
studies have compared the efficacy of these
agents in terms of reducing allergic
conjunctivitis symptoms caused by Japanese
cedar pollen. Therefore, we performed a
randomized controlled clinical trial to evaluate
the efficacy of olopatadine versus epinastine in
healthy Japanese adults with a history of allergic
conjunctivitis induced by Japanese cedar pollen
using a version of the CAC model (Ora-CAC).
METHODS
We performed a single-center (Biochemical
Research Center, Kitasato Institute Hospital,
Tokyo, Japan), double-blind, three-visit,
randomized study to compare the efficacy and
safety of olopatadine and epinastine for treating
allergic conjunctivitis induced by Japanese
cedar (Cryptomeria japonica). This study was
performed in compliance with the ethical
principles of the Declaration of Helsinki, the
Ethical Guideline for Clinical Studies stipulated
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by the Minister of Health, Labor and Welfare
(Japan), and the guidelines of the
Pharmaceutical and Medical Devices Agency
(Japan). The study was approved by the
institutional review board at Kitasato Institute
Hospital. The study was registered in the
University Hospital Medical Information
Network clinical trial registry (identifier:
UMIN000013943). An independent contract
research organization (Ora, Inc, Boston, MA,
USA, and Ora Japan KK, Osaka, Japan) designed
the study and provided study oversight. Subject
recruitment and study site coordination were
performed by Kitasato Institute.
Procedures
The Ora-CAC model, which is based on a
method described by Abelson et al. [11], was
used. In brief, Japanese cedar allergen was
prepared by Ora staff using standard
proprietary methods. Serial dilutions were
made and tested on volunteers in an
escalating dose fashion at Visit 1.
Confirmatory CAC with the highest
concentration of allergen determined
previously at Visit 1 was done at Visit 2. This
was the same concentration used at Visit 3.
Following this standard protocol, the study
comprised three clinical visits with
approximately 15 days between each visit. At
Visit 1 (Day -30 ± 3), potential subjects
underwent screening tests to determine their
eligibility. First, subjects were tested for skin
sensitivity to Japanese cedar pollen by injecting
a small amount of cedar pollen and saline as a
control using a Bifurcated NeedleTM (Tokyo M.
I. Company, Inc., Tokyo, Japan). Candidates
with negative skin reactions to Japanese cedar
pollen were excluded from the study.
Candidates with positive skin reactions (wheal
size C5 mm, erythema size C15 mm, or wheal
diameter at least twice the diameter of the
negative control) at Visit 1 underwent
subsequent titration CAC tests. In these tests,
the subjects were bilaterally administered with
Japanese cedar pollen (serially diluted in
buffered saline) into the conjunctival cul-de-
sac. After each dose, the severity of the allergic
reaction was assessed in terms of scores for
itching and hyperemia in the conjunctival
vessel bed. A positive CAC result was defined
as scores of C2 for itching (using a 5-point scale
with 0.5-unit increments, where 0 = none and
4 = incapacitating itching) and C2 for
hyperemia (using a 5-point scale with 0.5-unit
increments, where 0 = none and 4 = extremely
severe hyperemia) in both eyes within 10 min of
administration. If no response was observed at
10 min after administration, the subject was
administered with a higher concentration of the
solubilized allergen, which was repeated until a
positive test result was observed (scores of C2
for itching and C2 for hyperemia). The subjects
assessed and graded ocular itching before and
after the CAC. The investigator used
biomicroscopy to grade conjunctival
hyperemia. The findings of these assessments
were used to assess the subject’s eligibility.
Subjects who did not satisfy the criteria for a
positive CAC response to Japanese cedar pollen
were excluded from the study.
At Visit 2 (Day -15 ± 3), the subjects
underwent a bilateral CAC in which one drop
of Japanese cedar pollen solution was
administered at the concentration that elicited
a positive reaction at Visit 1. The subjects
assessed itching before and at 5, 7, and 15 min
after the CAC, as well as eyelid swelling and
tearing at 7, 15, and 20 min after the CAC. The
investigator assessed conjunctival hyperemia at
7, 15, and 20 min after the CAC. Subjects with
negative results were excluded from the study.
At Visit 2, a positive CAC reaction was defined
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as (1) itching scores C2 at 5 min and at either 7
or 15 min after administration, and (2)
hyperemia scores C2 in the conjunctival vessel
bed at two or more times (5, 7, or 15 min).
At Visit 3 (Day 1), all of the subjects with
positive allergen reactivity tests at Visit 1 and
Visit 2 who satisfied the eligibility criteria
returned to the clinic and were randomized to
receive one drop of olopatadine (olopatadine
HCl ophthalmic solution 0.1%, PATANOL
from Alcon Laboratories) in the left or right eye
(1:1 ratio) according to the assignment schedule
prepared by Ora Inc.; all subjects received one
drop of epinastine (epinastine HCl ophthalmic
solution 0.05%, ALESION from Santen
Pharmaceutical Co.) in the contralateral eye as
an active control. Both study drugs were used at
their marketed concentrations. All study drugs
were administered by a trained physician in a
double-blind manner. To ensure successful
blinding, Kitasato Institute purchased the study
drugs and re-labeled them as A and B according
to the treatment assignment. The investigator
who administered the study drugs was not
involved in the investigator-based assessments
of hyperemia. Administration of the study drugs
was confirmed by a second investigator.
Five min after administration of the study
drugs, the subjects underwent a bilateral CAC
in which one drop of the allergen solution was
administered to each eye at the concentration
that elicited positive reactions at Visits 1 and 2.
The subjects assessed itching at 5, 7, and 15 min
after administration of the allergen, and an
investigator blinded to the study group
assessed conjunctival hyperemia at 7, 15, and
20 min.
Study Population
The subjects comprised healthy Japanese males
or females aged C20 years living in Japan with a
history of allergic conjunctivitis. Volunteers were
recruited and registered as members. These
volunteers received screening tests as described
below. Key inclusion criteria included a positive
skin test reaction to Japanese cedar pollen at Visit
1, and positive bilateral CAC reactions to
Japanese cedar pollen at both Visits 1 and 2.
The main exclusion criteria included clinically
active allergic conjunctivitis (because CAC
should be conducted during the season without
the target pollens), active ocular infection,
preauricular lymphadenopathy, any ocular
condition that could affect the subject’s safety
or study parameters (e.g., narrow angle glaucoma
requiring medication or laser treatment,
clinically significant blepharitis, follicular
conjunctivitis, iritis, pterygium, or dry eye), or
histories of vernal keratoconjunctivitis, atopic
keratoconjunctivitis, or recent ocular surgery
and/or refractive surgery. All subjects provided
written informed consent at Visit 1.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study.
Efficacy Endpoints
The efficacy of the study drugs was assessed in
terms of itching and hyperemia scores at pre-
specified times after administering the allergen
in the CAC on Visit 3. The primary efficacy
outcome was ocular itching at 7 ± 1 min after
administering the allergen. Ocular itching in
both eyes was evaluated by the subject using a
5-point scale with 0.5-unit increments, where
0 = none and 4 = incapacitating itching. The
main secondary efficacy outcome was
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conjunctival hyperemia at 20 ± 1 min. The
investigator evaluated conjunctival hyperemia
in both eyes using biomicroscopy and graded
the severity of hyperemia using a 5-point scale
with 0.5-unit increments, where 0 = none and
4 = extremely severe hyperemia (large,
numerous, dilated blood vessels characterized
by unusually severe deep red color regardless of
chemosis and involving the entire vessel bed).
An ophthalmologist evaluated redness and
chemosis scores. The redness scale used was an
Ora standard proprietary scale with
photographs used in Ora-CAC studies [11].
The scale is not for widespread distribution.
Ophthalmologists were trained by Ora and had
scales available for reference when evaluating
redness. The primary and secondary efficacy
endpoints were chosen based on the
physiological responses to allergen instillation
[12]. For itching, which is caused by neuronal
activation, the peak was reported to occur about
5 min after instillation, while for conjunctival
hyperemia, clinically significant redness is
found at about 7 min and the peak usually
occurs between 15 and 20 min after instillation.
The results of a previous study suggested that
the responses to Japanese cedar pollen in
Japanese subjects are delayed [12] compared
with the responses to other allergens in
non-Japanese subjects [8]. Therefore, we
selected 7 min to determine the peak level
of itching and, because the onset of redness
shows a flatter time profile, we assessed
conjunctival hyperemia at 20 min after
instillation.
Supportive efficacy outcomes were ocular
itching at 5 ± 1 and 15 ± 1 min and
conjunctival hyperemia at 7 ± 1 and
15 ± 1 min; ciliary hyperemia, episcleral
hyperemia, chemosis, and eyelid swelling
scores at 7 ± 1, 15 ± 1, and 20 ± 1 min; and
the proportions of subjects with self-reported
tearing or mucous discharge at 7 ± 1, 15 ± 1,
and 20 ± 1 min. Ciliary hyperemia and
episcleral hyperemia in both eyes were
evaluated by investigator via biomicroscopy
using the same 5-point scale (0–4) used for
conjunctival hyperemia (Table 1). Chemosis
was evaluated by the investigator using a
5-point scale with 0.5-unit increments, where
0 = none and 4 = extremely severe. Eyelid
swelling was assessed by the subjects at 7 ± 1,
15 ± 1, and 20 ± 1 min using a 4-point scale
(without 0.5-unit increments), where 0 = none
and 3 = severe. Subject-assessed tearing and
investigator-assessed ocular mucous discharge
at 7 ± 1, 15 ± 1, and 20 ± 1 min were reported
as either absent or present in either eye. The
investigator who assessed conjunctival
hyperemia and supportive endpoints was
unaware of the study group.
Safety Endpoints
Conjunctival allergen challenge was intended
to induce allergic conjunctivitis in volunteers.
An adverse event can therefore be any
unfavorable and unintended sign (e.g., an
abnormal laboratory finding), symptom, or
disease occurring after the patient has been
administered any drug under this protocol,
without any judgment about causality. Safety
evaluations included best-corrected visual
acuity before the CAC at Visits 1–3; slit lamp
biomicroscopy before and after the CAC at all
Visits 1–3; physical examination (auscultation
and percussion); vital signs before the CAC at
Visits 1 and 3; and undilated fundoscopy after
the CAC at Visits 1 and Visit 3. Subjects were
surveyed about adverse events after the CAC at
Visit 1 and before and after the CACs at Visits 2
and 3.
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Table 1 Results of the supportive efﬁcacy endpoints






Before the CAC test 0.00 ± 0.00 0.00 ± 0.00 0.00 – –
7 ± 1 min 0.13 ± 0.28 0.19 ± 0.32 -0.06 0.0916 0.0832
15 ± 1 min 0.31 ± 0.45 0.39 ± 0.52 -0.08 0.0978 0.0882
20 ± 1 min 0.41 ± 0.53 0.49 ± 0.63 -0.08 0.1720 0.1594
Episcleral hyperemia
Before the CAC test 0.00 ± 0.00 0.00 ± 0.00 0.00 – –
7 ± 1 min 0.14 ± 0.30 0.20 ± 0.32 -0.06 0.0328 0.0324
15 ± 1 min 0.48 ± 0.64 0.56 ± 0.67 -0.08 0.1319 0.1319
20 ± 1 min 0.60 ± 0.76 0.74 ± 0.80 -0.14 0.0742 0.0751
Chemosis
Before the CAC test 0.00 ± 0.00 0.00 ± 0.00 0.00 – –
7 ± 1 min 0.11 ± 0.31 0.18 ± 0.35 -0.07 0.0182 0.0180
15 ± 1 min 0.43 ± 0.49 0.47 ± 0.49 -0.04 0.4171 0.4197
20 ± 1 min 0.52 ± 0.53 0.62 ± 0.58 -0.10 0.0738 0.0768
Eyelid swelling
Before the CAC test 0.00 ± 0.00 0.00 ± 0.00 0.00 – –
7 ± 1 min 0.04 ± 0.20 0.02 ± 0.14 0.02 0.4024 0.3222
15 ± 1 min 0.08 ± 0.27 0.12 ± 0.39 -0.05 0.2400 0.3222
20 ± 1 min 0.10 ± 0.30 0.22 ± 0.46 -0.13 0.0421 0.0569
Tearing, yes
Before the CAC test 0 (0) 0 (0) – – –
7 ± 1 min 2 (4.0) 2 (4.0) – – 1.000
15 ± 1 min 1 (2.0) 1 (2.0) – – 1.000
20 ± 1 min 1 (2.0) 3 (6.0) – – 0.1573
Mucous discharge, yes
Before the CAC test 0 (0) 0 (0) – – –
7 ± 1 min 1 (2.0) 1 (2.0) – – 1.000
15 ± 1 min 3 (6.0) 4 (8.0) – – 0.5637
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Statistical Analyses
The sample size was calculated based on the
itching scores reported in an earlier study that
compared olopatadine with epinastine using
the CAC test [8]. Fifty evaluable subjects were
needed to achieve 86% power with two-sided
a = 0.05 to show a statistically significant
difference between the two treatments.
The primary efficacy analysis was conducted in
the intent-to-treat (ITT) population using the last
observation carried forward (LOCF) method to
impute missing data. Analyses of secondary
outcomes and sensitivity analyses were
performed on the ITT population with observed
data only (ODO). Symptom scores were
summarized using descriptive statistics [mean,
standard deviation (SD), sample number (n),
median, and range] by treatment at each time
point for primary and secondary endpoints.
Treatment means and treatment differences
(olopatadine-epinastine) were estimated with
95% confidence intervals using analysis of
covariance (ANCOVA) with the mean score after
the CAC at Visit 2 (Day -15 ± 3) for each eye as a
covariate. This analysis was confirmed in
supportive analysis using the paired t test.
Hypothesis testing of the main secondary
variable was to follow the primary analysis if the
primary null hypothesis was rejected. Family-wise
error was controlled at 2.5% (one-sided) between
the primary and main secondary analyses.
Secondary efficacy variables were analyzed using
identical methods to the primary efficacy variable
in the ITT population with ODO. Safety variables
were analyzed descriptively in all randomized
subjects according to the assigned treatment,
when appropriate. No statistical comparisons
were made for safety variables. Data were
entered into Microsoft Excel version
14.0.7128.500 (64-bit), Redmond, WA, USA.
Data were analyzed using SAS version 9.2, SAS
Institute, Cary, NC, USA, for all of our analyses.
RESULTS
Study Subjects
Between December 2013 and January 2014, 103
subjects were initially screened of which 22 did
not meet the eligibility criteria at Visit 1, 24 did
not meet the eligibility at Visit 2, and 7 were
withdrawn because of the stated enrollment
capacity. Therefore, 50 subjects attended the
clinic at Visit 3 and were included in the
efficacy (ITT set) and safety analyses. There
were 28 males and 22 females. The mean ± SD
age was 33.3 ± 9.2 years (Table 2). The subjects
were equally randomized into two groups and
received olopatadine in the right or left eye
(n = 25 per group); epinastine was administered
into the contralateral eye. None of the subjects
withdrew from the study at Visit 3. Therefore,
all 50 subjects were included in the ITT, per
Table 1 continued




20 ± 1 min 2 (4.0) 4 (8.0) – – 0.3173
Values are mean ± standard deviation or n (%) for the intent-to-treat population with observed data only
CAC conjunctival allergen challenge
a Analysis of covariance
b Paired t test or McNemar test (tearing and mucous discharge)
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protocol (PP), and safety populations. In all
subjects, the study drugs were correctly
administered in the assigned eyes. Table 3
shows the scores for ocular itching and
conjunctival hyperemia at Visit 2.
Primary Efficacy Endpoint
The primary efficacy endpoint was the mean
itching score at 7 ± 1 min after allergen
administration in the CAC at Visit 3. As
shown in Fig. 1, the mean ± SD itching score
in the ITT population was 0.23 ± 0.31 in
olopatadine-treated eyes compared with
0.37 ± 0.44 in epinastine-treated eyes. The
treatment difference of -0.14 in favor of
olopatadine was statistically significant based
on ANCOVA (p = 0.0462). The difference was
also significant using the paired t test
(p = 0.0377). Identical results were obtained
when the ITT population was used with ODO.
Secondary Efficacy Endpoint
The secondary efficacy endpoint was
conjunctival hyperemia at 20 ± 1 min after
allergen administration in the CAC at Visit 3.
As shown in Fig. 2, the mean ± SD conjunctival
hyperemia scores were 0.89 ± 0.88 and
1.12 ± 0.95 for olopatadine and epinastine,
respectively. The treatment difference of -0.23
units in favor of olopatadine was statistically
significant based on ANCOVA (p = 0.0273). The
difference was also significant with the paired
t test (p = 0.026). Identical results were obtained
when the ITT population was used with ODO.
Supportive Efficacy Outcomes
In terms of supportive efficacy endpoints, the
mean ± SD ocular itching scores in the
olopatadine- and epinastine-treated eyes (ITT
population with ODO) were 0.22 ± 0.32 and
0.28 ± 0.39, respectively, at 5 ± 1 min, and were
0.22 ± 0.29 and 0.39 ± 0.50, respectively, at
15 ± 1 min. The treatment difference was
-0.06 at 5 ± 1 min based on ANCOVA
(p = 0.3199) or the paired t test (p = 0.2934).









n 25 25 50
Sex, n (%)
Male 14 (56.0) 14 (56.0) 28 (56.0)
Female 11 (44.0) 11 (44.0) 22 (44.0)
Age, years
Mean ± SD 33.1 ± 9.5 33.5 ± 9.1 33.3 ± 9.2
Range 20–49 21–53 20–53
SD standard deviation






Before the CAC test 0.00 ± 0.00 0.00 ± 0.00
5 ± 1 min 2.52 ± 0.50 2.53 ± 0.49
7 ± 1 min 2.71 ± 0.53 2.73 ± 0.50
15 ± 1 min 2.75 ± 0.65 2.78 ± 0.60
Conjunctival hyperemia
Before the CAC test 0.03 ± 0.12 0.03 ± 0.12
7 ± 1 min 2.19 ± 0.63 2.19 ± 0.64
15 ± 1 min 2.79 ± 0.64 2.81 ± 0.67
20 ± 1 min 2.83 ± 0.73 2.82 ± 0.73
Values are mean ± standard deviation for the intent-to-
treat population with observed data only
CAC conjunctival allergen challenge
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However, the treatment difference was -0.17 in
favor of olopatadine at 15 ± 1 min based on
ANCOVA (p = 0.0432) and the paired t test
(p = 0.0394).
The mean ± SD conjunctival hyperemia
scores in the olopatadine- and epinastine-
treated eyes (ITT population with ODO) were
0.26 ± 0.38 and 0.38 ± 0.48, respectively, at
7 ± 1 min, and were 0.76 ± 0.78 and
0.88 ± 0.88, respectively, at 15 ± 1 min. The
treatment difference was -0.12 at 7 ± 1 min
based on ANCOVA (p = 0.0010) and the paired
t test (p = 0.0008). The treatment difference was
-0.12 at 15 ± 1 min based on ANCOVA
(p = 0.0986) and the paired t test (p = 0.0008).
The mean ± SD episcleral hyperemia scores
in the olopatadine- and epinastine-treated eyes
(ITT population with ODO) were 0.14 ± 0.30
and 0.20 ± 0.32, respectively, at 7 ± 1 min. The
treatment difference was -0.06 at 7 ± 1 min
based on ANCOVA (p = 0.0328) and the paired
t test (p = 0.0324).
The mean ± SD chemosis scores in the
olopatadine- and epinastine-treated eyes (ITT
population with ODO) were 0.11 ± 0.31 and
0.18 ± 0.35, respectively, at 7 ± 1 min. The
treatment difference was -0.07 at 7 ± 1 min
based on ANCOVA (p = 0.0182) and the paired
t test (p = 0.018).
There were no differences in ciliary
hyperemia or the proportions of subjects with
self-reported tearing or mucous discharge
between the two treatments at any of the
measurement times
Safety
There were no adverse events during the study.
Furthermore, there were no abnormal findings
































Time Before CAC test 5 min 7 min (primary endpoint) 15 min 
Olopatadine Epinastine Olopatadine Epinastine Olopatadine Epinastine Olopatadine Epinastine 
Mean ± SD 0.00 ± 0.00 0.00 ± 0.00 0.22 ± 0.32 0.28 ± 0.39 0.23 ± 0.31 0.37 ± 0.44 0.22 ± 0.29 0.39 ± 0.50 
Difference 0.00 −0.06 −0.14 −0.17 
p = 0.3199 
p = 0.0462 
p = 0.0432 
Fig. 1 Effects of olopatadine and epinastine on the mean
ocular score at 5, 7, and 15 min after allergen administration
(Japanese cedar pollen) in the conjunctival allergen
challenge test. The primary efﬁcacy outcome was the mean
ocular itching score at 7 min. The analysis was not adjusted
for multiplicity at 5 or 15 min. Values are mean ± standard
deviation. Treatment differences and p values were
calculated by analysis of covariance. aMean ocular score
was assessed using a 5-point scale with 0.5-unit increments
ranging from 0 to 4. CAC conjunctival allergen challenge,
SD standard deviation
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fundoscopy, or physical examination at any
visit. There were no significant changes in visual
acuity or vital signs between Visits 1 and 3.
None of the subjects withdrew from the study
because of adverse events.
DISCUSSION
In this study, Japanese patients with a history of
allergic conjunctivitis to Japanese cedar pollen
underwent a single CAC test with exposure to
Japanese cedar pollen as the allergen. We found
that administration of olopatadine significantly
reduced self-assessed ocular itching at 7 min
(the primary endpoint) and investigator-
assessed conjunctival hyperemia at 20 min
(the main secondary endpoint) compared with
epinastine without apparent safety concerns.
These results support the use of olopatadine for
the treatment of allergic conjunctivitis caused
by Japanese cedar pollen. In a similarly designed
study, Abelson and Greiner [9] performed CAC
tests in 68 subjects and reported that
olopatadine 0.1% significantly reduced itching
and redness compared with levocabastine
0.05%. The authors also reported that
olopatadine was more tolerable than
levocabastine in terms of reduced discomfort
following administration. In another study in
which 32 subjects underwent CAC tests, Berdy
et al. [10] reported that olopatadine 0.1% was
more effective in reducing ocular itching than
ketotifen fumarate 0.025% while causing less





































Time Before CAC test 7 min 15 min 20 min (main secondary 
endpoint) 
Olopatadine Epinastine Olopatadine Epinastine Olopatadine Epinastine Olopatadine Epinastine 
Mean ± SD 0.05 ± 0.18 0.05 ± 0.18 0.26 ± 0.38 0.38 ± 0.48 0.76 ± 0.78 0.88 ± 0.88 0.89 ± 0.88 1.12 ± 0.95 
Difference 0.00 −0.12 −0.12 −0.23 
p = 0.0986 
p = 0.0273 
p = 0.0010 
Fig. 2 Effects of olopatadine and epinastine on the
conjunctival hyperemia scores at 7, 15, and 20 min after
allergen administration (Japanese cedar pollen) in the
conjunctival allergen challenge test. Hypothesis testing of
the main secondary variable (conjunctival hyperemia at
20 min) followed the primary analysis because the primary
null hypothesis (ocular itching at 7 min) was rejected.
Family-wise error was controlled at 2.5% (one-sided)
between the primary and main secondary analyses. The
analysis was not adjusted for multiplicity at 7 or 15 min.
Values are mean ± standard deviation. Treatment differences
and p values were calculated by analysis of covariance. aThe
conjunctival hyperemia score was assessed using a 5-point
scale with 0.5-unit increments ranging from 0 to 4. CAC
conjunctival allergen challenge, SD standard deviation
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olopatadine was preferred over ketotifen by
approximately three times as many patients.
In addition, Lanier et al. [8] reported that
olopatadine 0.1% was more effective than
epinastine 0.05% in controlling allergic
symptoms induced by a CAC test. Taken
together, the results of these studies support
the use of olopatadine 0.1% as an effective
treatment for preventing allergic conjunctivitis
and other ocular allergic symptoms. However,
data should be interpreted with caution because
there was no negative control group treated
with physiological saline.
In these earlier studies, the authors tested the
efficacy of ocular solutions using standardized
allergens in CAC tests, but did not include
Japanese cedar. Japanese cedar pollinosis is
thought to affect more than 19.4% of the
Japanese population [5], and may have
significant clinical and economic effects. It
presents with nasal symptoms such as
sneezing and rhinorrhea, as well as severe
ocular itching. So far, however, very few
studies have sought to identify options for
treating this allergic condition. Based on prior
studies, we hypothesized that olopatadine
would alleviate the severe symptoms of
Japanese cedar pollinosis, especially itching.
Indeed, the results of this study revealed that
olopatadine was associated with significantly
weaker allergic reactions in terms of itching and
conjunctival hyperemia compared with an
alternative active control (epinastine).
Olopatadine is also available as an oral drug
for treating systemic and non-ocular allergic
conditions. An earlier study compared the
efficacy and safety of oral olopatadine and
fexofenadine for treating the nasal symptoms
of Japanese cedar pollinosis [13]. The authors
reported that that olopatadine significantly
improved nasal symptoms (nasal congestion,
sneezing, and nasal discharge) and activity
impairment compared with fexofenadine after
exposure to Japanese cedar pollen in an
environmental exposure unit. The results of
that study and of our study highlight that
olopatadine is an effective treatment for the
nasal and ocular symptoms of Japanese cedar
pollinosis, although a combination of oral and
ophthalmic treatment may be required to
target all of the symptoms.
The reasons why olopatadine showed
superior efficacy (itching and redness relief) to
epinastine in this study and earlier studies
remain to be elucidated. One possible
explanation is that the two drugs show
different affinities for histamine receptors in
the conjunctiva, important targets for treating
allergic conjunctivitis and related allergic ocular
diseases [14]. Olopatadine was reported to have
a mixed antagonistic profile (competitive and
noncompetitive inhibition) against histamine
H1 receptors [15], whereas epinastine is a
competitive inhibitor. Accordingly,
olopatadine exhibited the greatest inhibitory
effects among the anti-histamines tested in that
study, acting in a concentration-dependent
manner. Another possibility is that
olopatadine also has anti-inflammatory effects,
which include suppression of interleukin (IL)-6
and IL-8 production by conjunctival epithelial
cells, by inhibiting a variety of histamine-
related signaling pathways [16]. Olopatadine
also has greater effects on mast cell stabilization
than epinastine [17, 18].
Some limitations of this study must be
mentioned. In particular, the efficacy of the
study drugs was assessed at a single visit after a
single exposure to Japanese cedar pollen in a
CAC test. Although the procedure is useful for
examining the efficacy of drugs against allergic
reactions induced by a specific allergen, the
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results of this study may differ if exposure
occurs for a longer time or if the drug is
administered at different effective
concentrations relative to the allergen
concentration used in the CAC. In addition,
because of the approach used in the present
study, we could not examine the cumulative
effects of exposure to the allergen or the effects
of treatment for several consecutive days or
weeks, which might be required in real-life
settings. It is also important to consider that
the results may not apply to allergic
conjunctivitis caused by other common
allergens. Finally, it is important to
acknowledge that the concentrations of the
olopatadine (0.1%) and epinastine (0.05%)
solutions differed. Although these are the
marketed solutions, the lower concentration of
epinastine may have led to lower
concentrations in the conjunctiva, limiting its
efficacy. Therefore, to directly compare the
pharmacologic activities of ophthalmic
solutions, future studies could use solutions
containing equivalent concentrations of the
active drugs to avoid this confounding factor.
Nevertheless, the current study allowed us to
compare the efficacies of the marketed products
themselves.
CONCLUSION
In conclusion, the results of this study suggest
that olopatadine 0.1% is more effective than
epinastine 0.05% at reducing the symptoms of
Japanese cedar pollen-induced allergic
conjunctivitis in CAC tests, a short-term
efficacy evaluation system. Prospective
randomized controlled trials in real-life
settings are needed to confirm these results
and the efficacy and safety of longer term
administration of olopatadine.
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